346 related articles for article (PubMed ID: 31333093)
1. Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives.
Al-Attraqchi OHA; Attimarad M; Venugopala KN; Nair A; Al-Attraqchi NHA
Curr Pharm Des; 2019; 25(25):2716-2740. PubMed ID: 31333093
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Potentials of A2B Adenosine Receptor Ligands: Current Status and Perspectives.
Chandrasekaran B; Samarneh S; Jaber AMY; Kassab G; Agrawal N
Curr Pharm Des; 2019; 25(25):2741-2771. PubMed ID: 31333084
[TBL] [Abstract][Full Text] [Related]
3. Novel approaches for targeting the adenosine A2A receptor.
Yuan G; Gedeon NG; Jankins TC; Jones GB
Expert Opin Drug Discov; 2015 Jan; 10(1):63-80. PubMed ID: 25311639
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor.
Rodríguez D; Gao ZG; Moss SM; Jacobson KA; Carlsson J
J Chem Inf Model; 2015 Mar; 55(3):550-63. PubMed ID: 25625646
[TBL] [Abstract][Full Text] [Related]
5. Adenosine A2A receptor as a drug discovery target.
de Lera Ruiz M; Lim YH; Zheng J
J Med Chem; 2014 May; 57(9):3623-50. PubMed ID: 24164628
[TBL] [Abstract][Full Text] [Related]
6. Potential Therapeutic Applications of Adenosine A
van Waarde A; Dierckx RAJO; Zhou X; Khanapur S; Tsukada H; Ishiwata K; Luurtsema G; de Vries EFJ; Elsinga PH
Med Res Rev; 2018 Jan; 38(1):5-56. PubMed ID: 28128443
[TBL] [Abstract][Full Text] [Related]
7. A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
Cacciari B; Spalluto G; Federico S
Mini Rev Med Chem; 2018; 18(14):1168-1174. PubMed ID: 29692248
[TBL] [Abstract][Full Text] [Related]
8. Integrating Pharmacophore into Membrane Molecular Dynamics Simulations to Improve Homology Modeling of G Protein-coupled Receptors with Ligand Selectivity: A2A Adenosine Receptor as an Example.
Zeng L; Guan M; Jin H; Liu Z; Zhang L
Chem Biol Drug Des; 2015 Dec; 86(6):1438-50. PubMed ID: 26072970
[TBL] [Abstract][Full Text] [Related]
9. 8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors.
Brunschweiger A; Koch P; Schlenk M; Rafehi M; Radjainia H; Küppers P; Hinz S; Pineda F; Wiese M; Hockemeyer J; Heer J; Denonne F; Müller CE
Bioorg Med Chem; 2016 Nov; 24(21):5462-5480. PubMed ID: 27658798
[TBL] [Abstract][Full Text] [Related]
10. Adenosine receptors and diabetes: Focus on the A(2B) adenosine receptor subtype.
Merighi S; Borea PA; Gessi S
Pharmacol Res; 2015 Sep; 99():229-36. PubMed ID: 26142494
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in the In-silico Structure-based and Ligand-based Approaches for the Design and Discovery of Agonists and Antagonists of A2A Adenosine Receptor.
Agrawal N; Chandrasekaran B; Al-Aboudi A
Curr Pharm Des; 2019; 25(7):774-782. PubMed ID: 30848185
[TBL] [Abstract][Full Text] [Related]
12. Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer.
Ferré S; Bonaventura J; Tomasi D; Navarro G; Moreno E; Cortés A; Lluís C; Casadó V; Volkow ND
Neuropharmacology; 2016 May; 104():154-60. PubMed ID: 26051403
[TBL] [Abstract][Full Text] [Related]
13. Blood Platelet Adenosine Receptors as Potential Targets for Anti-Platelet Therapy.
Wolska N; Rozalski M
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31684173
[TBL] [Abstract][Full Text] [Related]
14. Molecular modeling approaches for the discovery of adenosine A
Deb PK; Chandrasekaran B; Mailavaram R; Tekade RK; Jaber AMY
Drug Discov Today; 2019 Sep; 24(9):1854-1864. PubMed ID: 31103731
[TBL] [Abstract][Full Text] [Related]
15. Affinity Mass Spectrometry-Based Fragment Screening Identified a New Negative Allosteric Modulator of the Adenosine A
Lu Y; Liu H; Yang D; Zhong L; Xin Y; Zhao S; Wang MW; Zhou Q; Shui W
ACS Chem Biol; 2021 Jun; 16(6):991-1002. PubMed ID: 34048655
[TBL] [Abstract][Full Text] [Related]
16. Activation of adenosine A
Carlin JL; Jain S; Duroux R; Suresh RR; Xiao C; Auchampach JA; Jacobson KA; Gavrilova O; Reitman ML
Neuropharmacology; 2018 Sep; 139():268-278. PubMed ID: 29548686
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands.
Federico S; Spalluto G
Expert Opin Ther Pat; 2012 Apr; 22(4):369-90. PubMed ID: 22435652
[TBL] [Abstract][Full Text] [Related]
18. 5-Substituted 2-benzylidene-1-tetralone analogues as A
Janse van Rensburg HD; Terre'Blanche G; van der Walt MM; Legoabe LJ
Bioorg Chem; 2017 Oct; 74():251-259. PubMed ID: 28881253
[TBL] [Abstract][Full Text] [Related]
19. Targeting A3 and A2A adenosine receptors in the fight against cancer.
Merighi S; Battistello E; Giacomelli L; Varani K; Vincenzi F; Borea PA; Gessi S
Expert Opin Ther Targets; 2019 Aug; 23(8):669-678. PubMed ID: 31189400
[No Abstract] [Full Text] [Related]
20. Deciphering conformational selectivity in the A2A adenosine G protein-coupled receptor by free energy simulations.
Jespers W; Heitman LH; IJzerman AP; Sotelo E; van Westen GJP; Åqvist J; Gutiérrez-de-Terán H
PLoS Comput Biol; 2021 Nov; 17(11):e1009152. PubMed ID: 34818333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
